Genetic Variant Detection in Cancer: Using ISH to Track Tumor Evolution

Analyzing intratumor heterogeneity is essential for predicting therapeutic response. 

By The Scientist Creative Services Team | December 14, 2017


FREE Webinar

Thursday, February 1, 2018
2:30-4:00 PM Eastern Time
Register Now

Intratumor heterogeneity (ITH) is a major underlying cause of therapy resistance and disease recurrence, and is a read-out of how a tumor has grown. Current methods to analyze genetic ITH rely on the sequencing of ‘bulk’ or flow-sorted populations, in which the spatial context of tumor subclones is not preserved, and rare subclones may not be detected. These shortfalls can be addressed with BaseScope™ ISH–a unique mutation-specific RNA in situ hybridization assay. The BaseScope assay represents a significant technical advance for in situ mutation detection, and provides new insight into the mechanisms of tumor evolution with potential ramifications for selecting patients for treatment. Join us to learn more about this new approach to ITH analysis.

Topics to be covered:

  • How ITH influences treatment successes and failures
  • How the BaseScope ISH assay enables reliable detection of ITH

Register Now

Meet the Speakers:

Ann Marie Baker, PhD
Centre for Tumour Biology, Barts Cancer Institute
Queen Mary University of London



Courtney Anderson, PhD
Group Leader Applications
Advanced Cell Diagnostics



Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Could Rapamycin Help Humans Live Longer?
  2. Renowned Physicist Stephen Hawking Dies
  3. John Sulston, Human Genome Project Leader, Dies
  4. High-Fiber Diet Shifts Gut Microbes, Lowering Blood Sugar in Diabetics